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Objective: We hypothesized that DA and L-DOPA derived from nutritional tyrosine and the resultant observed postprandial plasma excursions of
L-DOPA and DA might affect glucose tolerance via their ability to be taken-up by beta cells and inhibit glucose-stimulated b-cell insulin secretion.
Methods: To investigate a possible circuit between meal-stimulated 3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine (DA) production in
the GI tract and pancreatic b-cells, we: 1) mapped GI mucosal expression of tyrosine hydroxylase (TH) and aromatic amino acid decarboxylase
(AADC); 2) measured L-DOPA and DA content of GI mucosal tissues following meal challenges with different L-tyrosine (TYR) content, 3)
determined whether meal TYR content impacts plasma insulin and glucose excursions; and 4) characterized postprandial plasma excursions of
L-DOPA and DA in response to meal tyrosine content in rodents and a population of bariatric surgery patients. Next, we characterized: 1) the
metabolic transformation of TYR and L-DOPA into DA in vitro using purified islet tissue; 2) the metabolic transformation of orally administrated
stable isotope labeled TYR into pancreatic DA, and 3) using a nuclear medicine technique, we studied endocrine beta cells in situ release and
binding of DA in response to a glucose challenge.
Results: We demonstrate in rodents that intestinal content and circulatory concentrations L-DOPA and DA, plasma glucose and insulin are
responsive to the tyrosine (TYR) content of a test meal. Intestinal expression of two enzymes, Tyrosine hydroxylase (TH) and Aromatic Amino acid
Decarboxylase (AADC), essential to the transformation of TYR to DA was mapped and the metabolism of metabolism of TYR to DA was traced in
human islets and a rodent beta cell line in vitro and from gut to the pancreas in vivo. Lastly, we show that b cells secrete and bind DA in situ in
response to glucose stimulation.
Conclusions: We provide proof-of-principle evidence for the existence of a novel postprandial circuit of glucose homeostasis dependent on
nutritional tyrosine. DA and L-DOPA derived from nutritional tyrosine may serve to defend against hypoglycemia via inhibition of glucose-
stimulated b-cell insulin secretion as proposed by the anti-incretin hypothesis.
 2019 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Pancreatic b-cells integrate several different external signals to fine-
tune the release of insulin and thus accurately regulate blood
glucose levels commensurate with metabolic demand. While
D-Glucose is the major physiological stimulus for insulin secretion,
fatty acids and some, but not all [1], amino acids promote insulin
secretion by b-cells either alone or in synergy with D-glucose. Net
insulin production and glucose homeostasis are regulated by a number
of other molecules as well, including several gut-derived peptide
hormones (e.g. GLP-1) and a number of classical neurotransmitters
(e.g. epinephrine). Many of these molecules function as amplifying
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Mesenteric organs synthesize the majority of the total “classical”
neurotransmitter dopamine and L-DOPA in the body from its biosyn-
thetic precursor Tyrosine (TYR) [3]. The foregut (including the stomach)
is the major source of secreted and circulating DA and L-DOPA [4,5].
After ingestion of a standard mixed meal (MMTT), healthy human vol-
unteers, as well as rodents, show up to two-fold over baseline increases
in plasma DA and L-DOPA concentrations [6,7]. The kinetics of DA and
L-DOPA excursions coincide with postprandial GLP-1 levels observed
after a mixed meal tolerance test (MMTT) administered to Lewis rats [8].
Both L-DOPA and DA inhibit glucose-stimulated insulin secretion (GSIS)
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pancreatic DA [11,14]. b-cells can import and store DA in insulin
storage vesicles [8,12] via the action of DA active transporter (DAT). b-
cells co-secrete DA as well as insulin in response to glucose stimulus
and express Vesicular Monoamine transporter type 2 (VMAT2),
dopamine 2 like receptors (D2R), and the large aromatic amino acid
transporter, LAT1, responsible for the import of L-DOPA [8,12,15].
Experiments with dopamine antagonists suggest that the co-secreted
dopamine binds to D2R to down-regulate b-cell insulin secretion [12].
Most recently, murine b-cell-specific knockout of D2R or D3R lose the
phenotype of DA-mediated inhibition of GSIS in vivo [13].
The exact mechanism(s) underlying the reversal of hyperglycemia in
response to bariatric surgery is currently unknown, but several
biochemical mechanisms accounting for improvements of glucose
homeostasis with Roux-en-Y gastric bypass surgery (RYGB) indepen-
dent of weight loss have been proposed (reviewed in [16,17]). Two are
of particular interest; a) the “hindgut hypothesis” suggesting that
nutrient delivery to the distal intestine drives the production of
“incretins” which enhance insulin secretion (e.g. GLP-1), and b) the
“foregut hypothesis.” The foregut hypothesis proposes that foregut
bypass reduces the elaboration of nutrient-stimulated intestinal signals
(e.g. anti-incretins) that limit insulin secretion, and normally defend
against hypoglycemia thereby maintaining homeostasis [18e20]. We
set out to examine the role of nutritional TYR as a source of possible
“anti-incretins” in healthy rodents.
2. MATERIALS AND METHODS
2.1. Materials
Table S1 contains information regarding the source of reagents and
equipment used in these studies.
2.2. Human studies
The Columbia University Institutional Review Board approved the study;
written informed consent was obtained from all patients. Participants
were recruited from patients who presented for surgical treatment of
obesity. Standard criteria for performing bariatric surgery were used
for selection of obese patients e BMI40 kg/m2 or BMI35 kg/m2 in
the presence of obesity related co-morbidities [21]. Patient and
surgeon determined the choice of surgical procedure. The surgical
procedures were performed in the standard accepted fashion [22].
Twenty-two patients were studied before or 6e12 months after
surgery: RYGB (n ¼ 5); LSG (n ¼ 12). Seven pre-operative controls
with BMI35 and  75 kg/m2 were included. Four patients in the
preoperative group, 2 patients in the RYGB group and 4 subjects in the
SG group had diagnoses of diabetes mellitus. For measurements of the
DA and L-DOPA mixed meal responses, a 320 kcal liquid mixed-meal
challenge (Optifast, 50% carbohydrate, 35% protein, 15% fat)
consumed within a 15 minute period, was administered. Venous blood
(approximately 5 ml) was drawn into EDTA tubes, in the fasted state
and 15, 30, and 60 min after the meal. Venous blood samples were
coded such that the surgical status of patient remained unknown to the
analysis laboratory until the end of the study. Plasma was separated
from whole blood by centrifugation at room temperature at 500g.
Plasma samples were analyzed immediately for DA by HPLC-EDC or
frozen at 80 C for batched analysis of L-DOPA by ELISA.
2.3. Animal studies
Castrated male Yorkshire crossbred pigs were obtained at 8 weeks of
age (about 16 Kgs). Castrated Yucatan miniature swine were obtained
at 2e3 months of age (<30 kgs). Male Lewis rats were obtained at 8e38 MOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier G
Downloaded for Anonymous User (n/a) at Columbia University
For personal use only. No other uses without permission. C10 weeks of age. Male Goto-Kakazaki rats were obtained at 8 weeks of
age. All animals were allowed at least one-week accommodation in the
husbandry facilities of the Institute of Comparative Medicine at
Columbia University Medical Center. Rodents were housed under
conditions of controlled humidity (55 5%), temperature (23 1 C),
and lighting (lights on 0600e1800 h) with access to standard labo-
ratory rat chow and water ad libitum. Goto-Kakazaki rodents were fed
NIH #31M rodent diet. The rats were handled daily to minimize
nonspecific stress before the experiments began. In most experiments,
it was necessary to measure blood glucose in fasting animals.
For these groups, the food was removed 8 hr before glucose levels
were tested. All animal studies conducted following protocol approval
and according to the guidelines of the Columbia University Medical
Center Institutional Animal Care and Use Committee and the NIH Guide
for the Care and Use of Laboratory Animals.
2.4. Cell lines and pancreatic islets source
INS-1E cells were obtained from AddexBio, Inc. and cultured according
to their instructions. Purified cadaveric human islets were obtained
from the Integrated Islet Distribution Program (IIDP) funded by the
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK). Neonatal Yorkshire porcine islets were prepared at the Alberta
Diabetes Institute of the University of Alberta as previously described
[23] and shipped overnight to the laboratory. Lewis Rats islets were
prepared as previously described [24].
2.5. Mixed meal and oral glucose tolerance testing
Eight hour fasted rats were anesthetized (5% for induction and 1.5e
1.0% for maintenance, isoflurane in 90% O2 at 4.0 L/minute); ocular
ointment was applied, and rats were given 1.5 mL subcutaneous
warmed sterile normal saline for fluid replacement and placed prone on
a heated 37 C surface throughout the procedure. Six different gavage
solutions were prepared; 1) Ensure-original formula used neat from the
bottle, 2) Tyros 2 reconstituted to be isocaloric with Ensure (0.24 grams
Tyros 2 powder per ml water), 3) Tyros 2 supplemented with tyrosine
and phenylalanine (both at 2.5 mg/ml), 4) 50% Dextrose solution, 5)
50% Dextrose with tyrosine at 12 mg/ml and 6) Tyros 2 reconstituted
and supplemented with 20 mg/ml stable isotope labeled L-tyrosine
(13C9,99%, 15N 99%). Following induction of anesthesia, baseline
samples of blood were drawn and whole blood glucose concentration
measurements were performed with an Alphatrak glucometer. Rodents
were then gavaged at 4 uL/gram body weight. Venous blood was
sampled (about 300 mL) from the lateral tail vein at 0, 15, 30, 45 and
90 min following gavage. Whole blood was transferred into EDTA
microcentrifuge tubes and maintained in ice. Tubes were centrifuged at
500g for 15 minutes, and plasma was collected and analyzed
immediately for insulin and or monoamine content or stored at80 C.
2.6. Insulin,GLP-1 and L-DOPA ELISA measurements
Measurements of Insulin, GLP-1, and L-DOPA in plasma samples were
performed by ELISA following the manufacturer’s instructions.
Absorbance measurements were performed using a Biotek Synergy 2
plate reader.
2.7. Extraction of tissue monoamines
Approximately forty-five minutes following gavage, anesthetized Lewis
rats were euthanized by CO2 inhalation. The rodent’s abdomen was
injected with about 50 ml of 4 C normal saline and the upper GI tract
from the esophagus to the ileocecal junction (including the spleen and
pancreas) harvested en bloc and placed in chilled saline. Proceeding
stepwise, first, the stomach was divided from the block, and washed inmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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chilled saline to remove residual contents. Tissue was sampled
(approximately 10 mm2) from glandular antrum blotted dry and placed
in pre-weighed tubes (2 ml capacity containing 1 ml of 0.2 M
perchloric acid, 0.1 mM EDTA and 1.5 mm Zirconium beads). These
steps were repeated along the GI tract, with samples taken at 1 cm
intervals. The ligament of Treitz was used to demarcate the duodenum
(first 2 cm from the stomach) from the jejunum (at about one cm from
the ligament) and the ileum (preceding two cm from ileocecal junction).
In those experiments, using Tyros supplemented with stable isotope
labeled L-tyrosine, only pancreas or brain tissue was harvested at the
indicated time. Tissue was homogenized for 2 min at 4 C using a
Mini-Beadbeater-16 instrument. Homogenates were maintained an
additional 30 minutes on ice, then spun at 18,000g for 15 min at
4 C. The supernatants were harvested and adjusted to pH 3.0 with 1M
sodium acetate. The cleared homogenates were then filtered through
0.2 mm PTFE syringe filters for subsequent analysis by high-
performance liquid chromatography-electrochemical detection
(HPLC-ECD) or liquid chromatography electrospray ionization tandem
mass spectroscopy (LC-ESI-MS/MS).
2.8. Measurements of monoamines by HPLC-ECD
For measurements of DA in patient samples, a solid phase extraction
technique was used to prepare plasma samples for high-performance
liquid chromatography with electrochemical detection (HPLC-ECD).
One ml of patient serum was mixed with one ml of 1.0 M Tris buffer,
pH 8.5 and approximately 30 mg of activated, basic, Brockmann type 1
aluminum oxide. The slurry was rotary mixed for 30 minutes at 10 rpm.
The alumina oxide was allowed to completely settle, the supernatant
removed and replaced with 2.0 ml of Milli Q water. This was repeated
for three washes. The alumina oxide was transferred to 0.2 mm nylon
Microspin centrifuge filters. The alumina oxide was spin-dried for 3
minutes at 2700g. Bound monoamines were eluted by centrifugation
in 0.2 M perchloric acid (PCA), 0.1 mM EDTA for analysis by HPLC-
ECD. For measurements of L-DOPA and DA in rodent serum sam-
ples, solid phase extraction was not feasible. Instead, fresh plasma
was precipitated with 10% PCA for 30 min on ice, spun at 18,000g
and the supernatants analyzed by HPLC-ECD. Samples were trans-
ferred to amber vials and placed in the autosampler. HPLC was per-
formed as follows; 10 ml of sample or standard was injected into a
high-pressure liquid chromatography with an electrochemical detector
using Eicompak SC-50DS (3.0 ID x 150 mm) column prefaced with
3 mm ID x 4 mm AC-ODS guard column. The flow rate was 500 uL/
minute with a column temperature set to 25 C. The mobile phase was
20% Methanol (LC-MS grade), 80% 0.08 M Citrate-Acetate pH 3.5
buffer with 205 gms/L Sodium Octane Sulfonate and 4 mg/L
EDTA-2Na. The analytes were eluted isocratically and detected with a
carbon graphite electrode (WE-3G) with an applied potential of 750 mV
vs Ag/AgCl. Time versus peak current data was collected and analyzed
using the Eicom Envision EPC-700 chromatography software. Prior to
and following each sample run, authentic standards were run at
100 pg/ml, 10 pg/ml, 1 pg ml and 0.1 pg/ml to create a calibration curve.
These standards were norepinephrine, L-DOPA, DOPAC, DA, 5-HIAA,
isoproterenol, HVA, 3-MT, and 5 HT. The detection limits for L DOPA
and DA in plasma under these conditions were around 30 fmoles and
20 fmoles, respectively. An L-DOPA ELISA was used in confirmatory
studies during methods development.
2.9. Positron emission tomography study of D2R occupancy in
swine pancreata
The night before and the morning of the study, animals were food
restricted but allowed free access to water. In the indicatedMOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier GmbH. This is a
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administered admixed into each of the three daily meals for two days
prior to the PET scan. Alternatively, in some experiments, Haloperidol
at 1 mg/kg was administered 60 minutes before the start of the PET
scan. Swine were sedated with an intramuscular injection of 3e5 mg/
kg of tiletamineezolazepam combination followed by induction with
propofol (2 mg/kg). Once the loss of jaw tone and palpebral reflex was
observed, the pigs were intubated and maintained on isofluorane at
3e4% in O2. Swine were catheterized for venous access on both ears.
For transport to the PET suite, isofluorane was withdrawn and
additional sedation was provided via intermittent boluses of propofol
(1 mg/kg) via a normal saline i.v. drip. Upon arrival, swine were
returned to isofluorane inhalation anesthesia at 1.5e3% in O2. Body
temperature was monitored by a rectal temperature probe and
maintained at w38 C by a heating pad. Swine were placed supine
and head in the PET scanner to allow venous access once the swine’s
abdomen was in the correct field of view. PET scans were performed
on a Biograph mCT PET/CT camera with a reconstructed spatial res-
olution of approximately 4 mm. Data were acquired for 180 min. A low-
dose abdominal computerized tomography (CT) scan, guided by the
CARE Dose4D program (120 kV, 50e350 mA), was performed at the
beginning of each session for the collection of attenuation mapping and
anatomical data. Dynamic PET measurements were acquired in 3D
mode over an axial field of that covered 22 cm beginning near the
xiphoid process and extending caudally over the abdomen. List mode-
acquired PET data were reconstructed into 24 (3 h) dynamic frames
with increasing frame duration using an iterative ordered subset
expectation maximization algorithm (4 mm FWHM, Hann filter, two
iterations/24 subsets) with CT-based attenuation, time-of-flight scat-
ter, random, scanner dead time, detector normalization, and radio-
active decay corrections as provided by the manufacturer’s software.
The final reconstructed images had a matrix size of 168  168  74
and a voxel size of 4  4  3 mm. 18F-Fallypride in a sterile saline
vehicle was obtained from PETNET solutions with the typical end-of-
synthesis specific activity of 200 MBq/nmol. Fasting blood glucose
measurements performed at this revealed an average BG of
68  4 mg/dL 18F-Fallypride (mean dose of 204  13 MBq) was
administered as a bolus over 2e3 min immediately after the initiation
of the scan. The mean specific activity of 18F-Fallypride at the time of
injection was 22  15 MBq nmol1. There was no statistically
significant difference in injected mass at baseline and following
challenge. A normal saline flush was performed after the injection of
tracer for baseline scans. In the indicated experiments, the saline flush
was substituted with 50% Dextrose at 1 ml/kg. The glucose challenge
was performed via the i.v. route, rather than p.o, because the animals
were anesthetized, intubated and the delivery of glucose to the
endocrine pancreas was more precise and predictable within the time-
frame of optimal tracer delivery to the pancreas using the i.v. route.
The glucose challenge scans were performed within 4e6 weeks
following the baseline scan.
2.9.1. Quantification of PET data
From the reconstructed PET and CT data, a fused image was provided
by the Syngo software. The frame by frame reconstructed PET data
were analyzed with PMOD software. Volumes of interest were
manually drawn on summed images to generate the time activity
curves for pancreas (Body and Tail) and spleen. Radioactivity in all VOIs
was calculated as the mean radioactivity concentration (KBq/mL). To
generate standardized uptake values (SUVs) the VOI activities were
normalized to the injected dose and corrected for animal weight. Next,
using the spleen as reference tissue input, 18F-Fallypride D2R bindingn open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 39
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(Bavail), was calculated for the combined body and tail of the pancreas
using the reference tissue model, MRTM2 in PMOD as previously
described [25]. MRTM2 utilizes kinetic data to estimate BPND but
BPND itself represents the equilibrium ratio of specifically bound to
nondisplaceable tracer (free plus non-specifically bound, assumed to
be the same in all tissues at equilibrium). The effect of radiolabeled
metabolites on the percent change following glucose or pharmaco-
logical challenges can be approximated in the equilibrium setting. In
brain, the fractional change is
ðCsðbaseÞ  CsðpostÞÞ=CsðbaseÞ
where Cs(base) and Cs(post) are the equilibrium concentrations of
specifically bound (to D2R) tracer at baseline and after the challenge.
Under the assumptions that i) metabolism of the radiotracer is unaf-
fected by the challenge and ii) the equilibrium nondisplaceable tracer
concentrations are the same in pancreas and spleen, the fractional
difference in BPND across conditions in pancreas is
ðCsðbaseÞ  CsðpostÞÞ=ðCsðbaseÞ þ CmðpanÞ þ CmðsplÞÞ
where Cm (pan) and Cm (spl) are the radiolabeled metabolite con-
centrations in pancreas and spleen. To the extent that the radiolabeled
metabolites accumulate similarly over time in both tissues, the percent
change in BPND will approximate the percent change in specific
binding of the tracer. The early phases (<10 minutes) of the tracer
TACs reflect VOIs with minimal 18F-Fallypride metabolites contami-
nation [26].
2.10. In vitro isotopomer labeling studies
Human islets were cultured for 24e36 hrs following receipts in non-
adherent T175 flasks at 37 C. The transport media was replen-
ished daily with fresh CMRL-1066 medium, supplemented with 1.5%
human albumin, 0.1% insulin-transferrin-selenium (ITS), Penn/Strep,
5 ml of 1M HEPES, and 14.5 ml of 7.5% Sodium Bicarbonate. INS-1E
cells were cultured in RPMI 1640 medium supplemented with HEPES,
glutamine, sodium pyruvate and -mercaptoethanol as previously
described [8]. A tyrosine free modification of this media was prepared
and supplemented with 5% BSA and 5% dialyzed fetal calf serum.
Islets (400 IEQ/well) or INS1E cells (confluent 100 cm2 flasks) were
cultured overnight in the tyrosine-free media. Cultures (viability> 90%
by trypan blue exclusion) were then supplemented with 2 mM L-
tyrosine (Ring-13C6, 99%) or 10 mM L-DOPA (Ring-D3, 98%). Where
indicated cultures were also supplemented with 10 uM pargyline, 10
uM Moclobemide and 10 uM GBR 12909 to inhibit catabolism of DA. At
the indicated times, culture supernatants were harvested and cell/islet
perchloric acid extracts prepared. Supernatants (5 ml) were processed
by solid phase extraction as described above. PCA cell extracts were
cleared by centrifugation. Samples were then purified by HPLC as
described above and sample fractions corresponding to the elution
times of L-DOPA and DA collected and frozen at-80 C for later LC-ESI-
MS/MS analysis.
2.10.1. LC-ESI-MS/MS
Dopamine isotopic enrichment was determined as native dopamine
and as the n-propyl derivative [27] (diester, amide) by LC-MS/MS
(Shimazu UFLCXR, QTRAP 6500) by negative electrospray ionization.
Three parent-daughter ion pairs were monitored to confirm peak
identification as dopamine (154/137, 154/119, and 154/91), or as its
n-propyl derivative (322/137, 322/210, and 322/266). A gradient
elution Solvent A: aqueous ammonium acetate 12 mM, Solvent B:40 MOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier G
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Luna 5u C8, 100A, 150 4.6 mm, 5 microns) was used for dopamine
(gradient: 5e20% solvent B) and the dopamine n-propyl derivative
(gradient: 50e70% solvent B). Isotopic enrichments were determined
by monitoring parent-daughter ion pairs of dopamine (and the n-propyl
derivative) formed from the labeled precursor: dopamine mþ3 from [2,
5, 6-D3] L-Dopa, dopamine mþ6 from ring [13C3]tyrosine, and
dopamine mþ9 from [13C9, 15N]tyrosine. Tyrosine isotopic enrich-
ment was determined following derivatization as the n-trifluoracetyl-n-
butyl ester [28]by Chemical ionization GC-MS (Agilent: HP-1 column,
G1530A GC, and 5975C MS) using isobutane as the reagent gas, He
gas at a flow rate of 1 ml/min was the carrier, and a temperature
program ramped from 100 to 200 C.
2.11. Immunohistochemistry
Rodent foregut and pancreas or swine pancreas tissue were fixed in
4% paraformaldehyde in 0.2M phosphate buffer and paraffin
embedded using standard methods. Sections were cut at 5 mm
thickness and antigen retrieval was performed in 10 mM citric acid,
0.05% Tween 20, pH 6.0 at 96 C for 15 min. We used Anti tyrosine
hydroxylase, anti-aromatic amino acid decarboxylase, anti-VMAT1,
anti-chromogranin A, Anti-insulin [29] and Anti-Dopamine 2 like
receptor [30] antibodies at dilutions of 1:500, 1:500, 1:1000, 1:2,000,
1:2,000 and 1:500, respectively. We visualized the immune complexes
with FITC- or CY3-conjugated secondary antibodies. DAPI staining was
used as a nuclear marker. Stained sections were imaged on an epi-
fluorescent microscope equipped with an Infinity 2 monochrome CCD
camera. Images were processed with the Infinity Analyze software.
2.12. Assessment of VMAT2 protein expression by western blot
assay
Lewis rats’ tissues, including purified islets, were homogenized in
10 mmol/l Tris homogenization buffer (pH 7.4) with Halt protease in-
hibitors cocktail added as per the manufacturer’s recommendations.
The samples were centrifuged at 14,000g for 30 min at 4 C and the
supernatant collected for western blot assay. Protein concentrations of
the supernatants were determined by the BCA method and 15 mg
protein of each sample was loaded onto the 10e20% SDS gel,
separated by electrophoresis in a tris-glycine buffer and transferred to
nitrocellulose (NC) membrane. The membranes were blocked in
blocking buffer (5% nonfat milk) for 2 h at room temperature and then
were incubated with rabbit anti-VMAT2 polyclonal IgG AB1598P
overnight at 4 C. After being washed three times for 10 min with
washing solution, the membranes were incubated with goat anti-rabbit
IgG-HRP and immunoreactive bands were visualized by an ECL
Western blotting detection kit using a FluorChem M System. The im-
ages were analyzed using Alphaview software.
2.13. Live cell microscopy
Pig islets were cultured in complete Ham’s F10 medium for 2e3 days
at 37 C, 5% CO2 and 95% air in non-treated culture flasks. Islets were
then washed in Hanks balanced salt solution and treated with 0.25%
Trypsin, 0.1% EDTA in HBSS to effect islet dispersal to single cells. The
suspensions were washed and then filtered through sterile nylon 100
um mesh filter. Cells were transferred to RPMI1640 without Phenol
Red but supplemented with 10% glutamine, 10 mM HEPES, 1%
penicillin/streptomycin and 1% FBS and 5% BSA and plated at 2mls/
well in poly-lysine coated 0.17 mm thick glass coverslip chamber
slides (Lab-Tek II) for overnight culture. Adherent islet cell cultures
were treated with 10 uM DnsykD-1 probe at 1000 x the Kd. Some
cultures received 1 mM Haloperidol in addition to DnsykD-1. CellmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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cultures were maintained at 37 C in 5% CO2 and 95% air, until imaged
at 5, 15, 30, and 45 minutes after the addition of DnsykD-1. Cells were
imaged with Zeiss Axiovert 135 inverted microscope equipped with a
heated platform (Warner, CSH-1), a single channel temperature
controller (Warner, TC-324C), a 385 nm LED source (Thorlabs,
M385LP1) and 400 nm long pass emission filter. Images were
captured with a Lumenera Infinity 2 monochrome CCD camera. Images
were processed with the Infinity Analyze software.
2.14. Analysis of D2R and VMAT2 expression by RT-PCR
Total RNA from INS-1 E cell line, purified pancreatic islets, purified
acinar tissue, and rat brain were isolated using the RNeasy Lipid Tissue
Mini Kit. cDNA from porcine tissues was generated using the VILO
cDNA synthesis kit (from 1 mg of the isolated total RNA). Retro Tran-
scription of total RNA from rat tissues and INS-1 E cells has been
instead done using the 30 RACE System for Rapid Amplification of
cDNA Ends, according to the instructions provided by the manufacturer
(from 4 mg of the isolated total RNA). To perform PCR assays the
amount of cDNA obtained retro-transcribing 30 ng total RNA was used
in each reaction for pig tissues, 100 ng of total RNA for rat brain and
INS-1 E, and 250 ng for purified rat islets RNA. AccuPrime Pfx
SuperMix was used for semiquantitative PCR assays at the conditions
recommended by the manufacturer; varying the annealing temperature
and the extension time on the basis of the couple of primers used. All
the primers (Table S2) were synthesized by Invitrogen Custom Primers
except for the AUAP (Abridged Universal Amplification Primer) that is
included in the 30 RACE System. The PCR products were run on a 2%
agarose gel in 1X TAE buffer, stained with a 3X GelRed Nucleic Acid
Gel Stain solution, imagined and quantified by densitometry using
Alphaview software.
2.15. Data analysis and statistics
Descriptive and comparative statistic including the arithmetic means,
standard errors of the mean (SEM), Mann Whitney U test, Students t-
testing and parametric and nonparametric repeated measure ANOVA
were calculated using Medcalc software. Data are presented as the
Mean  1 SEM. The significance of comparisons (p values) of sta-
tistical means was calculated using the 2-tailed Student’s t-test unless
indicated otherwise. P values < .05 were considered statistically
significant. The significance of differences in tissue monoamine con-
tent kinetics was calculated using Friedman’s nonparametric repeated
measure ANOVA or in the case of human L-DOPA and DA excursions, a
standard parametric repeated measure ANOVA was applied
3. RESULTS
3.1. GI tissue content of L-DOPA and DA is responsive to the
tyrosine content of the mixed meal stimulus
Using immunohistochemistry with previously validated antibodies, we
studied the expression of TH and AADC in the foregut (i.e. stomach and
small bowel) of the rat (Supplemental Materials, Figure S1). These
enzymes are responsible for the conversion of tyrosine to L-DOPA and
the conversion of L-DOPA to DA, respectively. Both TH and AADC were
expressed in cells of the gastric mucosa, occasional enteroendocrine
cells in the intestinal mucosa and throughout the lamina propria (or
illeal submucosa) of the small bowel, confirming and extending pre-
vious results [5,31]. We also analyzed the expression of vesicular
monoamine transporter type 2 gene (VMAT2) in rat tissues, including
pancreatic islets (purified from the pancreas of Lewis rats) and total
brain, either at level of protein (by western blot) and as accumulation of
specific RNA (by semi-quantitative RT-PCR) (Supplemental Materials,MOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.com
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pancreatic islets as previously reported [32] and the presence of
VMAT2 transcripts in INS-1 E, a rat insulinoma cell line used as a
model of in vitro insulin secretion [10].
Previous studies in rodents have demonstrated that the concentrations
of L-DOPA and DA in the stomach, small and large intestines fall or rise
during fasting and feeding, respectively [33,34]. To investigate whether
L-DOPA and DA content of the GI tissue was responsive to TYR content
of a meal, we measured the concentration of L-DOPA and DA in the
foregut and hindgut (i.e. stomach to ileum including pancreas). Tissues
were obtained from Lewis rats in the fasting state, after a standard
mixed meal (Ensure), and after an isocaloric mixed meal prepared with
a TYR and PHE-free food powder (Tyros 2). Additional tissue was
obtained from rats feed with Tyros 2 supplemented with TYR and PHE to
the levels present in the standard mixed meal formula (Ensure). We
found that the GI tissue content of DA and L DOPA (Figure 1) varied
significantly depending on fasted/fed state and the type of meal chal-
lenge administered. MMTT with Ensure resulted in higher concentra-
tions (p < 0.05) of DA in antral and duodenal tissue relative to fasting,
consistent with previous studies [33]. When the mixed meal stimulus
was performed with Tyros 2, all tissues studied showed significantly
reduced levels of DA (p< 0.05) relative to fasted rats or rats fed Ensure.
MMTT with Tyros 2 supplemented with free TYR and PHE significantly
increased tissue contents of DA to levels equivalent to or higher than
those following MMTT with Ensure. Non-parametric ANOVA indicated
that GI tissue DA concentrations were not significantly different between
fasting or Ensure-fed rats. However, Tyros 2-fed rats had significantly
lower GI tissue DA content than fasting or Ensure-fed rodents
(p < 0.05). GI tissue Dopamine content (expressed as pg analyte/mg
wet tissue weight) of rodents given Tyros 2 supplemented with TYR and
PHE was significantly higher (p < 0.5) than that measured in the other
groups. Changes in L-DOPA content of GI tissue were quantitatively less
than DA content changes. The L-DOPA content of GI tissue in Ensure-
fed rodents was generally higher than that of fasted rodents (p< 0.05).
Tyros 2 feeding reduced upper GI tissue levels of L-DOPA to those
present in fasted animals (p < 0.05). Tyros 2 supplemented with TYR
and PHE meal stimulus showed significantly higher levels (p< 0.05) of
L-DOPA along most of the GI tract.
3.2. Relationship of glucose tolerance and insulin secretion to
tyrosine content of the meal stimulus
To investigate whether nutritional tyrosine might influence glucose
tolerance, we performed oral glucose tolerance tests with and without
added free tyrosine in Lewis rats to isolate the role of tyrosine in
glucose homeostasis (Figure 2). The metrics of glucose tolerance for
these experiments, including rodent weights, mean fasting glucose
and insulin concentrations, mean glucose and insulin area-under-the-
curve (AUC) as wells as the HOMA-IR and Matsuda indices of insulin
sensitivity and the statistical significances of the observed differences
are summarized in Table 1. Relative to glucose alone insulin excur-
sions (insulin AUC) were significantly decreased when glucose and TYR
was administered. A repeated measures ANOVA of the blood glucose
data also revealed a significant difference in the kinetic profiles of
glucose versus glucose plus TYR (p < 0.05). The presence of TYR in
the oral glucose solution was associated with a significant (p < 0.005,
two-tailed Students t-test)) elevation in the 90-minute blood glucose
concentration relative to the oral glucose solution alone. Goto-Kakazaki
rats are a well-accepted rodent model of T2D [35] that has been
studied in the context of bariatric surgery [36]. We performed OGTT
testing in this model (with and without TYR) and obtained similar
results to our experiments in Lewis rats (Figure S3).n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 41
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Figure 1: G.I. tissue L-DOPA and DA content is responsive to the tyrosine and phenylalanine content of the mixed meal stimulus. Male Lewis rats (n ¼ 4 per group) were
gavaged with isocaloric mixed meal formulas that differed in tyrosine (TYR) and phenylalanine (PHE) content. Forty-five minutes after gavage, the rodents were euthanized, and
tissue from the gut and pancreas was harvested and analyzed for L-DOPA (white bars) and DA (black bars) content using two technical replicates. The mean wet tissue weight
normalized monoamine content along the GI tract for each stimulus is displayed. A non-parametric repeated measure ANOVA (Friedman’s test) was applied to the data set revealing
that GI tissue L DOPA and DA content in Tyros 2 fed animals was significantly lower (p < 0.05) from the three other conditions. Likewise GI tissue L-DOPA-DA content in Tyros
2 þ TYR/PHE was significantly higher (p < 0.05) from the three other conditions. The statistical significance of the differences between MMTT-Tyros and MMTT-Tyros þ TYR/PHE
stimulated L-DOPA and DA tissue content was performed using a two-tailed Students t-test. Error bars represent the standard error of the mean (SEM). Only the statistical
significances of the measured differences between Tyros2 and Tyros2 with TYR/PHE are shown (* ¼ p < 0.05).
Original Article3.3. Relationship of glucose tolerance and insulin secretion to the
tyrosine content of the mixed meal stimulus
Oral glucose tolerance testing demonstrated that glucose excursion
were significantly higher in the presence of exogenous oral tyrosine.
Aside from demonstrating a possible mechanism for the defense
against hypoglycemia, creating glucose intolerance was not of
particular preclinical interest. We returned to the mixed meal tolerance
testing we described for the measurements of gut tissue L-DOPA and
DA content experiments. To investigate whether differences in mixed
meal stimulus tyrosine content affected glucose homeostasis, we
performed MMTT in normoglycemic Lewis rats using Ensure and an
isocaloric dose of Tyros 2 (i.e. PHE/TYR depleted liquid meal formula).
Based on the previous experiments, we posited that an MMTT with
Tyros 2 would result in lower circulating glucose concentrations and
larger insulin excursions (Figure 3). The metrics of glucose tolerance
for these experiments, including rodent weights, mean fasting glucose
and insulin concentrations, mean glucose and insulin area-under-the-42 MOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier G
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sensitivity, the Insulinogenic index and the statistical significances of
the observed differences are summarized in Table 1. As predicted, the
plasma insulin excursions were significantly increased when Tyros 2
was substituted for the Ensure MMTT stimulus. Comparison of the
blood glucose concentration versus time profiles obtained with Ensure
versus Tyros 2, showed the Tyros 2 AUC was significantly lower than
the Ensure MMTT AUC. We also examined GLP-1 excursions in this
model. We did not find any significant differences (p ¼ 0.54) in the
GLP-1 excursions in response to Ensure (n ¼ 5, AUC ¼ 1091  57
pM*min) compared to Tyros 2 (n ¼ 6, AUC ¼ 995  130 pM*min) as
determined by the areas-under-the curve.
3.4. L-DOPA and DA excursions following a tyrosine depleted meal
stimulus or bariatric surgery are smaller relative to controls
There are significant post-prandial excursions of plasma DA and
L-DOPA following a mixed meal challenge in both humans [4,7] andmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 2: Exogenous tyrosine affects oral glucose tolerance and insulin secretion. Lewis rats were gavaged with a dextrose solution with or without L-tyrosine.
Measurements of whole blood glucose concentrations and plasma measurements of insulin were made in the serial plasma samples. Individual plasma insulin concentrations were
obtained from two technical replicates. Left panel, Time versus whole blood glucose concentration. The excursions were significantly different (p < 0.02) by a repeated measures
Bonferroni-corrected ANOVA. Right panel. From the time versus insulin concentration profiles, the area-under-the-curve was calculated. The insulin excursions in the presence of
glucose and tyrosine (OGTT W/TYR) were significantly smaller relative to the excursion measured with glucose alone (OGTT). Error bars represent the SEM. From a representative
experiment in a series of two.rodents [8]. Based on our studies of rodent GI tissue L-DOPA and DA
content following various mixed meal challenges (Figure 1), we
hypothesized that plasma excursions of L-DOPA and DA would vary
according to the meal stimulus (Figure 4, Left panels). As predicted,
the plasma excursions, as reflected by the AUCs, of both L-DOPA and
DA were significantly smaller (Table 2) when the TYR/PHE depleted
Tyros 2 meal stimulus was substituted for the standard mixed meal
challenge Ensure.
Others and we demonstrated that foregut tissue (i.e. stomach and
duodenum) contain significant amounts of TH and AADC, two enzymes
responsible for the conversion of TYR to L-DOPA and DA. Bariatric
surgeries such as sleeve gastrectomy (SG) and Roux-en-Y gastric
bypass (RYGB) exclude the nutrient path from much of these tissues
containing TH and AADC. We hypothesized that exclusion of nutrients
containing TYR from these tissues might result in changes in the
L-DOPA and DA excursions normally seen after MMTT and similar to
those observed when an isocaloric, but TYR depleted liquid meal was
substituted. To test this idea, we performed a cross-sectional study of












OGTT 5 408  28d 96  11 11.1  3 11499  85
OGTT w/TYR 6 362  104 75  4 8.5  1 15154  12
p Valuef 0.41 0.42 0.29 0.047
MMTT 7 249  18 128  8 50.1  8 15272  12
Tyros 2 8 254  18 103  7 60.7  17 12476  29
P Value 0.85 0.11 0.58 0.046
a Number of male rodents per group. From one representative experiment in a series of t
b HOMA-IR calculated as described in [37].
c Matsuda index of insulin sensitivity calculated as described in [38].
d Results are presented as mean  standard error of the mean.
e From time versus concentration profiles, the areas-under-the-curve were calculated by
f p values calculated using a two-tailed Students t-test.
g Ii, Insulinogenic index ((min*IuU/ml)/(min*mg/dL)) calculated as described in [39].
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versity Medical Center. The twenty-two bariatric surgery subjects
studied were 7 obese pre-operative patients (PO), 10 patients after
laparoscopic sleeve gastrectomy (SG), and five patients after RYGB
(subject characteristics presented in Table 3). Serial measurements of
plasma L-DOPA and DA were obtained during the MMTT. The kinetics
of elaboration of L-DOPA and DA e as reflected in serial serum assays
- were significantly different among the patient groups (Figure 4, right
panels). RYGB surgery patients had significantly smaller plasma
L-DOPA and DA excursions than the PO subjects as reflected in the
area-under-the-curves (AUCs) comparisons (Table 2). There was a
trend toward lower plasma DA AUC concentrations in the SG population
relative to the PO subjects that did not reach statistical significance.
However, if only the mean 60 min serum DA concentration was
considered, there was a significant difference in DA levels (p < 0.05,
two-tailed t-test) between the SG patients and PREOP patients. The
concentration vs. time profile of plasma L-DOPA in the SG patients was
significantly different from that of the PREOP and RYGB patients










9e 3804  540 17  5 4.5  0.7 0.33  0.22
62 1511  334 12  5 7.1  1.2 0.10  0.03
0.004 0.29 0.18 0.0003
45 3849  1138 16  2 1.61  0.2 0.26  0.03
3 7782  3980 17  6 1.64  0.3 0.59  12
0.027 0.84 0.93 0.023
wo.
the trapezoidal rule.
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Figure 3: Tyrosine content of the meal stimulus affects glucose tolerance and plasma insulin excursions. Male Lewis rats were gavaged with Ensure or isocaloric TYR/PHE
free Tyros 2, followed by serial blood sampling over a 90 min. period. Measurements of whole blood glucose concentrations (left panel) and plasma measurements of insulin
(right panel) were made in the serial samples. Error bars represent the SEM. Plasma insulin concentrations obtained from two technical replicates. From a representative
experiment in a series of two.
Original ArticleDA excursions measured in RYGB patients where most similar to those
excursions observed when a TYR depleted liquid meal was substituted
for the normal Ensure stimulus (Figure 4 comparison of right and left
panels).
3.5. Determining the metabolic fate of oral tyrosine
Our rodent glucose tolerance experiments suggested that TYR might
be an important modulator of glucose homeostasis. To understand
better the metabolism of TYR and its relationship to glucose homeo-
stasis, we traced the transformation of oral tyrosine into dopamine
stored in beta cells. We showed that human cadaveric islets, and the
rodent INS1E b-cell, transformed isotopically-labeled (deuterated)
L-DOPA and [13C] labeled tyrosine into dopamine in vitro. Cells and
islets were incubated in tyrosine-free media and the cultures treated
with either labeled L-DOPA or L-tyrosine. After the indicated incubation
period, catecholamines were purified from the culture supernatants or
cell extracts by high-performance liquid chromatography and analyzed
by liquid chromatography-electrospray ionization tandem mass spec-
troscopy. Percent isotopic enrichments for L-DOPA and DA were
calculated for each condition (Figure S4). Both human islets and INS1E
cells metabolized L-DOPA into DA as reflected by the enrichment
stable isotope-labeled DA or L-DOPA, extending and confirming pre-
vious studies [40]. Human islets metabolized both L-DOPA and TYR
into DA. The conversion of TYR and L-DOPA into DA was enhanced in
the presence of inhibitors of DAT (GBR12909) and MAO (pargyline and
moclobemide). MAO catalyzes the oxidation of DA into 3,4 dihydrox-
yphenylacetic acid.
Next, we repeated the Tyros 2 MMTT rodent experiments, substituting
tyrosine with stable isotope-labeled tyrosine. At the indicated interval
following gavage, the rodents were euthanized and the pancreas
harvested for measurements of isotopic enrichment of DA (Table 4).
We found that oral tyrosine [13C9,15N] became detectable in plasma
as early as 60 minutes after gavage of rodents with Tyros 2 supple-
mented with tyrosine [13C9,15N]. Pancreatic dopamine [13C8,15N], a
metabolic derivative of tyrosine [13C9,15N], was estimated to be
enriched relative to baseline to approximately 3% at 60 and 90 minutes
and to over 4%, at 120 minutes, respectively, following gavage. For
purposes of comparison and as a control, we measured the isotopic
enrichment of dopamine in whole brain tissue at 120 minutes following
gavage. The enrichment of dopamine [13C8,15N] was approximately44 MOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier G
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pancreas.
3.6. PET imaging of pancreatic D2R occupancy following in vivo
islet glucose-stimulated DA secretion
One element of the proposed glucose homeostasis regulatory circuit
suggests that glucose challenge results in the release of DA from beta
cell vesicular stores and subsequent inhibition of GSIS via binding to D2R
expressed by beta cells. To assess whether b-cell stores of dopamine
are released and bind to b-cell dopamine receptors in situ, we applied
an experimental paradigm used to measure dopamine receptor occu-
pancy in the CNS [41]. Briefly, in the CNS, measurement of D2R
occupancy (by DA) is performed by competition with the moderate
affinity D2R PET ligand, 18F-Fallypride [42]. The human CNS imaged
with 18F-Fallypride at baseline and then a second time, following
amphetamine challenge, demonstrates a significant loss of bound PET
ligand in the striatum [42]. Administration of amphetamine or cocaine is
known to increase extracellular striatal DA concentrations [43], and the
loss of bound PET ligand signal is due to endogenous DA competing with
18F-Fallypride for dopamine receptor occupancy. Similarly, the drug
alpha-methyl-para-tyrosine (AMPT), an inhibitor of tyrosine hydroxylase
and dopamine synthesis, when administered to subjects prior to PET
scan with certain D2R PET ligands, reveals higher PET ligand binding as
a result of the loss of competition with endogenous DA [44].
We used swine as our model system because of the physiological
similarity between human and swine islets. In swine the pancreas
volume of interest approaches that found in humans and is about 100 x
larger than that of rats, allowing for accurate quantification of the PET
ligand signal. We quantified D2R occupancy in swine pancreata using
the D2R PET ligand 18F-Fallypride at baseline (all fasting blood glucose
concentrations were 68 mg/dL), and following i.v. glucose challenge
(0.5 gm/Kg body weight) using Binding Potential (BPND) as the
outcome measure. In the brain, BPND is directly related to the receptor
density in the observed tissue [45]. The bloodebrain barrier prevents
radiolabeled metabolic byproducts of the breakdown of 18F-Fallypride
from entering the brain, but in tissues external to the brain, radio-
labeled metabolites are likely to contribute to the signal. Still, under
reasonable assumptions (see Methods), the change in BPND following
glucose or pharmacological challenges will reflect the changes in
dopamine binding to D2R-like receptors in the pancreas.mbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 4: Plasma L-DOPA and DA excursions in response to Mixed Meal Testing in a population of Lewis rats and Bariatric Surgery patients. Left panels. Male Lewis
rats were gavaged with Ensure or isocaloric TYR/PHE free Tyros 2, followed by serial blood sampling over a 90 min. period. Measurements of whole blood glucose concentrations
(left panel) and plasma measurements of L-DOPA and DA (Left panel) were made by HPLC-ECD in the serial samples. Plasma monoamine concentrations obtained from two
technical replicates. Right panels. Preoperative control patients (PO), patients with vertical sleeve gastrectomy (SG) and patients with Roux-en-Y-gastric bypass (RYGB) were given a
mixed meal tolerance test, followed by serial blood sampling over a 60 minute period. DA measurements were performed by HPLC-ECD. L-DOPA measurements were performed
by ELISA. Measurements of plasma L-DOPA and dopamine obtained from two technical replicates. Error bars are the SEM. The individual profiles of each RYGB patient are
presented rather than the mean excursions shown for the PO and SG populations.Pancreatic dopamine type 2 receptor expression overlaps anatomically
virtually exclusively with insulin expression in swine pancreas
(Figure S5). In support of this finding, we analyzed D2R and vesicular
monoamine transporter type 2 (VMAT2) expression, by RT-PCR, in
purified swine islets relative to the impure exocrine tissue by-product
of the islet purification. D2R and VMAT2 transcripts were significantly
enriched in islets relative to acinar tissue (Figure S6). Next, we
demonstrated that dopamine mimetic ligands bind to islets in vitroTable 2 e Summary of L-DOPA and DA excursions following MMTT.





MMTT 9 53.3a 2.6 143.5 4.8
Tyros 2 8 2.4 0.8 28.0 5.1
p-value 0.04 0.03
PO 7 32.6 6.8 55.3 12.0
SG 10 24.0 4.0 50.6 17.4
RYGB 5 13.3 2.9 10.6 5.2
p-value
PO vs SG 0.03 0.65
PO vs RYGB 0.014 0.005
a Plasma monoamine concentrations determined by HPLC with ECD detection from
two technical replicates.
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suppression (Figure S8).
PET quantification of total pancreatic bound18F-Fallypride provides a
suitable denominator for estimating the density of D2R in the endocrine
pancreas in vivo [46,47]. PET scans with 18F-Fallypride readily visu-
alized the porcine pancreas (Figure 5). Volumes of interest were placed
over reconstructed PET images of the pancreas and the D2R free
spleen reference tissue to obtain the kinetic profiles of 18F-Fallypride
binding represented as time versus activity (TAC) data (Figure 4, left
panel). From the TAC data (Figure 6, left panel), we estimated the
pancreatic density of D2R (expressed as BPND) for each animal studied










Preoperative (PO) 3/4 454a 0 4/7 0
Sleeve Gastrectomy (SG) 4/6 37  1 23  4 4/10 1.5
Roux-en-Y Gastric
Bypass (RYGB)
3/2 30  1 32  3 2/5 2.7
a Demographic measures presented as Mean  S.E.M.
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Table 4 e Oral Tyrosine is transformed into pancreatic DA.






Percent isotopic enrichment (mean  s.e.m)
0b <0.01 <0.01 <0.1
60 5.2  0.2 p < 0.003c 3.1  1.8 p < 0.001c n.d.
90 1.8  0.3 3.8  2.1 n.d.
120 1.1  0.5 4.4  1.4 2.1  0.6 p < 0.02c
a Lewis rats were gavaged with Tyros 2 supplemented with 20 mg/ml stable isotope labeled L-tyrosine (13C9,15N). At the indicated times blood samples were drawn and the rodents
were euthanized and the pancreas and/or whole brain tissue harvested. Plasma tyrosine and tissue dopamine isotopic enrichment for each sample (triplicate determinations) was
measured for each time point by LC-ESI-MS/MS. Plasma and tissue enrichments are the average of enrichment at t ¼ 0 (n ¼ 2), t ¼ 60 (n ¼ 2), t ¼ 90 (n ¼ 2), and t ¼ 120 min
(n ¼ 2). n.d. not done.
b The baseline t ¼ 0 time isotopic enrichment of [13C9,15N] Tyrosine and [13C8, 15N] dopamine was measured and found to below the detection threshold of the instrument. It is
estimated to be the product of the natural isotopic abundances of 13C and 15N.
c The 60, 90, and 120 min plasma isotopic enrichment values of [13C9,15N] Tyrosine or pancreatic dopamine isotopic enrichment values were pooled and compared to the measured
baseline abundance of [13C9,15N] Tyrosine or [13C8, 15N] dopamine using a ManneWhitney test. Results from a single experiment.
Original Articlespecifically bound radioligand in the region of interest (e.g. pancreas)
to that of nondisplaceable radioligand in tissue (here estimated by
measurements of radioligand concentration in the receptor-free spleen
reference region) and is proportional to the density of receptors
available to bind radioligand in vivo [48]. In pancreas and spleen,
radiolabeled metabolites likely contribute to the measured PET signal,
but these should have a modest effect on the percent change in BPND
following a glucose challenge. We found that glucose challenge (in the
form of an intravenous glucose tolerance test, IVGTT) resulted in sig-
nificant decreases (paired t-test, p < 0.0001) in the apparent D2R
density, a finding consistent with in situ DA release by b-cells in
response to glucose challenge. Of note, were the early changes (<10
minutes) in the post glucose challenge TAC of 18F-Fallypride, when the
presence of potentially confounding metabolites is minimal [26].
We performed two additional control experiments: 1) PET scans
following inhibition of dopamine synthesis by AMPT administration
showed higher BPND values, consistent with the hypothesis that tissue
dopamine depletion leads to greater availability of D2R to bind 18F-
Fallypride; and 2) swine treated with Haloperidol, a D2R antagonist,
showed a lower apparent density of D2R as reflected by the BPND
(Figure 6, far right panels). The measured changes in the TAC profile
seen after glucose stimulation (i.e. IVGTT) were unlikely due to re-
ductions in pancreatic blood delivery of tracer as the administration ofFigure 5: PET scans with 18F-Fallypride visualize the porcine pancreas.
Abdominal PET/CT images (axial vial view) recorded after an intravenous bolus injection
of 18F-Fallypride (153 MBq) in YMP-3. The PET portion of the image (color overlay)
represent the 0e180 minute summed image. P, Pancreas, S, Spleen. Image from a
representative scan of six animals.
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flow [49].
4. DISCUSSION
We set out to provide proof of principle that DA and L-DOPA derived
from nutritional tyrosine might be involved in the defense against
hypoglycemia as postulated by anti incretin hypothesis. The concept
that a neurotransmitter physiologically suppresses insulin secretion
as a fail-safe system defending against hypoglycemia was originally
proposed by Sharp et al. [50]. For example, rodent insulin secretion is
inhibited by the monoamine neurotransmitter, norepinephrine,
released locally from sympathetic innervation of the pancreas or
produced by the adrenal medulla and reaching islets via their unique
capillary system. Neuronal modulation (via innervation of the pancreas)
of b-cell insulin secretion, however, may differ in rodents and humans.
Relative to the structure of mouse islets, human islets are sparsely
innervated with few contacts by autonomic and cholinergic axons.
Moreover, in human islets, sympathetic axons are associated with
blood vessel smooth muscle cells located around the islet rather than
being in direct contact with b-cells [51]. To reconcile the apparent
autonomy of human islets with the known effects of autonomic
stimulation on islet hormone secretion, it was suggested that “spill-
over” from innervation or reduced islet microcirculation might be
responsible for downstream effects of autonomic neurotransmitters on
insulin secretion [52].
Previously published clinical studies provide anecdotal evidence for a
direct role of GI-derived DA and L-DOPA in glucose homeostasis. These
include:1) aromatic amino acid decarboxylase-deficient individuals
suffer from hypoglycemia [53], 2) patients with Parkinson’s disease
receiving oral dopamine precursor L-DOPA display reduced insulin
secretion during oral glucose tolerance testing [54]; and 3) there is an
inverse correlation between circulating concentrations of C-peptide
and DA [55].
Our studies demonstrate that oral TYR affects rodent insulin excursions
(i.e. insulin AUCs). Plasma insulin concentration kinetics are the
reflection of insulin sensitivity [56] and competing metabolic process
including insulin clearance (e.g. hepatic and extrahepatic insulin
clearance) and insulin production (i.e.beta cell insulin secretion). The
derivative outcome measures of insulin resistance, sensitivity, and
Insulinogenic index (i.e. HOMA-IR, Matsuda and Ii, respectively)
calculated for the rodent experiments suggest that changes in insulin
excursion are actually due to changes in beta cell insulin secretion
rather than changes in insulin sensitivity. While such an interpretationmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 6: Intravenous glucose stimulation results in loss of 18F-Fallypride tracer binding in the porcine pancreas. Left panel, Representative pancreas and spleen timee
activity curves for swine injected with a bolus of 18F-Fallypride chased with normal saline or glucose (0.5 gm/Kg). Right Panel, The binding potential with respect to the
nondisplaceable compartment (BPND) of 18F-Fallypride in the swine pancreas VOI was calculated using the spleen as the reference region for each experimental condition.
Following i.v. glucose challenge, BPND was significantly reduced compared to fasting conditions (average fasting BPND ¼ 2.3  0.2 (S.E.M), average post i.v. glucose
BPND ¼ 1.2  0.2, p < 0.0001, two-tailed paired t-test). Each separate data point is labeled with the swine ID #. BPND increased following interruption of dopamine synthesis with
AMPT and decreased following D2R receptor occupancy by haloperidol (n ¼ 2 animals for each condition).of the secondary outcome measures (i.e HOMA-IR, Matsuda composite
index and the Insulinogenic Index) in rodents should be viewed with
caution, the overall finding, that beta cell function is affected by oral
tyrosine is concordant with in vitro results and anecdotal clinical evi-
dence. The effects of DA on insulin secretion in vitro and the observed
postprandial excursions support the hypothesis that gut-derived L-
DOPA and DA delivered via the circulation impact insulin secretion and
postprandial glucose levels, perhaps in defense against hypoglycemia.
We previously provided evidence that DA mediates a glucose-
stimulated insulin secretion (GSIS) paracrine/autocrine inhibitory
circuit in human b-cells in vitro. In this circuit, DA synthesized de novo
or imported by dopamine (reuptake) transporter (DAT) is stored in
b-cell insulin granules by the action of the vesicular monoamine
transporter type 2 (VMAT2) [12]. In our model, we hypothesized that: 1)
DA and/or L-3,4-dihydroxyphenylalanine (L-DOPA) is synthesized from
tyrosine, released from the gut and is present in the circulation [this
current study and [7,8]] to the beta cells; 2) L-DOPA is transformed to
DA (by DOPA decarboxylase) in the beta-cells and/or; 3) DA is taken up
by DAT in the beta-cells [12]; 4) DA, at basal fasting concentrations
found in peripheral circulation, does not efficiently act to dampen in-
sulin secretion, until 5) it is concentrated by the actions of VMAT2 for
vesicular storage and released in high concentration near DA receptors
(similar to synapse) [57]. This formulation does not exclude the direct
action of circulating dopamine (following release from the GI) on beta
cells in synergy with that of locally released dopamine or an indirect
action of DA on somatostatin-expressing cells that have also been
shown to express limited amounts dopamine receptors [58].
During GSIS, DA and insulin are released and D2R is delivered to the
cell surface where it binds DA. DA, signaling through D2R, is a
powerful inhibitor of GSIS. The action of DA on insulin secretion may
extend to the subcellular level as well, as DA has recently been shown
to complex with and stabilize the non-active insulin hexamer, shifting
the equilibrium between hexamers and free insulin towards the non-
active hexameric form [59]. These findings offer a mechanism forMOLECULAR METABOLISM 23 (2019) 37e50  2019 The Authors. Published by Elsevier GmbH. This is a
www.molecularmetabolism.com
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A weakness of our study is that the mechanisms leading to the release
of intestinal L-DOPA and/or DA into the circulation remain unknown.
Presumably, VMAT1-positive enteroendocrine cells and AADC-positive
mucosal cells (see Figure S1) are involved in the release of DA and L
DOPA, respectively. In man, oral tyrosine alone results in a transient
increase of DA in plasma [34], suggesting that the release may be
passive. On-the-other-hand, the finding that intestinal DA stores are
depleted following MMTT relative to the fasting state suggests that
release may be mechanically stimulated. Specification of these details
will require experimental models not yet available to us. Another
weakness of our study is that only 2 of our RYGB patients had a previous
diagnosis of T2DM and that our studies were cross sectional rather than
longitudinal. Further studies of these patient populations are warranted.
Bariatric surgery is an effective treatment for obesity and its associated
comorbidities, including type 2 Diabetes Mellitus (T2D) [61]. Although
improvement in insulin resistance secondary to weight loss and a
decrease in fat mass are significant contributors to the improvement
and reversal of T2D, reduced insulin resistance alone does not fully
account for the efficacy of specific types of metabolic surgery.
Improved b-cell function, as well as improvement in hyperglycemia,
has been observed in surgeries where the upper portions of the
gastrointestinal (GI) tract are bypassed and/or removed. These effects
seem to be, at least in part, independent of weight loss [17]. We
observed similar patterns of L-DOPA and DA excursions in rodents
given a TYR/PHE free liquid meal stimulus and in RYGB patients given a
complete meal stimulus. Given that RYGB surgery excludes the nutrient
path from much of the tissues containing TH and AADC, we speculate
the common cause to be less downstream inhibition of GSIS. Other
metabolic similarities between rodents treated with Tyros 2 and mixed
meal tolerance testing in RYGB patients are present. It is well docu-
mented that postprandial insulin and C-peptide excursions are
increased early following RYGB [62e64], independent from weight-n open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). 47
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Original Articleloss. Tyrosine depleted Tyros 2 treated rodents also showed increased
insulin excursion relative to the complete mixed meal formula, a
finding that is possibly relevant to the observation that hyperinsulinism
is a known comorbidity of patients with Tyrosinemia type 1 treated with
reduced TYR/PHE diets [65]. Recent metabolomics studies in humans
clearly demonstrated that RYGB surgery is associated with lower
serum concentrations of Tyrosine and/or Phenylalanine [66,67,68.].
Further confirmation of reduced L-DOPA and DA excursions as the
basis of the early post-surgical improvement in hyperglycemia
observed when RYGB is used to treat T2DM associated with obesity
awaits more in-depth human longitudinal studies.
We used a PET tracer study to showing glucose-dependent
displacement of the dopamine analog 18F-fallypride in porcine
pancreas region of interest to demonstrate a final link the proposed
hypoglycemia defense circuit. However, PET quantification of total
pancreatic bound 18F-Fallypride in the fasting state may have more
practical applications. The amount of bound tracer might represent a
surrogate measure of b-cell mass given the restriction of D2R
expression to islets beta cells in the pancreas. The difference between
total pancreatic bound 18F-Fallypride at baseline and total pancreatic
bound 18F-Fallypride after glucose challenge might also represent a
measure of b-cell function. The ratio of these two measures, a beta
cell mass-normalized functional value, could have utility in the vetting
of therapeutic agents for the management of T2D.
Lastly, we propose that some elements in this circuit may represent
druggable targets for the manipulation of glycemia. The first step in the
conversion of TYR to DA involves TH. The specific inhibitor of TH, alpha-
methyl tyrosine, enhances both basal and glucose-stimulated insulin
secretion in vitro [12] and in vivo [69]. We previously demonstrated that
specific VMAT2 inhibitor compounds have potent in vivo glucose-
lowering effects in a rat model [11,70]. On a cautionary note, others
and we have shown that certain atypical antipsychotic drugs (APDs)
increase insulin secretion from islets in vitro [12,71] while others have
shown similar effects in vivo, both in rodent models [13,72,73] and
humans [74,75]. The common denominator among the mechanisms of
action of many typical and atypical antipsychotic drugs (APD) (e.g.
Risperidone, Amisulpride) is their antagonism of D2R, a distal element of
our proposed gut-to-beta cell regulatory circuit. Both typical and APDs
have significant metabolic side effects including significant weight gain,
hypertension, and heightened risks of development of T2D [76].
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